Wanbury Limited — Updates, 29-05-2025: Press Release

Wanbury Limited reported 23% YoY revenue growth to ₹172 Cr in Q4 FY25, led by higher volumes in key APIs post plant upgrades. EBITDA jumped 65% to ₹31.5 Cr, supported by efficiency gains and backward integration, while PAT rose 154% to ₹20.3 Cr, showing strong operational leverage. The company refinanced ₹95 Cr of debt at 12.5% interest, lowering financial costs. New launches include branded Hematinic tablets and Ketamine Hydrochloride API. Its Tanuku plant passed Brazil’s ANVISA audit without observations. Digital transformation with SAP S/4HANA is in progress to enhance agility.